Other studies have unambiguously demonstrated that AnxA6 may be useful to detect minimal residual disease in B-lineage acute lymphoblastic leukemia [111], the progression of melanomas [112] and squamous cervical cancer carcinogenesis [113]. This evidence concerns the gene ANXA6 and cervical squamous cell carcinoma.